Lixisenatide News

Lixisenatide currently has 12 news articles, with 20 predicted indications.

This page combines the AI-predicted indications for Lixisenatide with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Original indication: Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with...
Evidence level: L5
Predicted indications (20):
- opsismodysplasia (97.6%)
- focal stiff limb syndrome (97.5%)
- classic stiff person syndrome (97.5%)
- thiamine-responsive dysfunction syndrome (97.2%)
- diabetes mellitus (disease) (97.2%)
- drug-induced localized lipodystrophy (96.2%)
- pancreatic agenesis (96.0%)
- centrifugal lipodystrophy (96.0%)
- pressure-induced localized lipoatrophy (95.9%)
- idiopathic localized lipodystrophy (95.7%)
- autoimmune oophoritis (82.0%)
- type 1 diabetes mellitus (79.3%)
- cholangiocarcinoma, susceptibility to (65.4%)
- atrial flutter (disease) (64.5%)
- hemoglobin C-beta-thalassemia syndrome (64.3%)
- hypercarotenemia and vitamin A deficiency, autosomal recessive (62.0%)
- retinal dystrophy with or without extraocular anomalies (61.8%)
- pancreas, dorsal, agenesis of (60.9%)
- familial chronic myelocytic leukemia-like syndrome (60.5%)
- lymphopenic hypergammaglobulinemia, antibody deficiency, autoimmune hemolytic anemia, and glomerulonephritis (60.0%)